uploads/2017/12/Chart-004-3-1.jpg

Behind Sanofi’s Genzyme Business in 3Q17

By

Updated

Sanofi Genzyme  

Sanofi’s (SNY) genzyme business is the company’s specialty care product franchise and reported revenues of 1.63 billion euros in 3Q17, representing a 12.5% YoY (year-over-year) rise in operating revenues. This included revenues from emerging markets.

After excluding revenues from emerging markets, this franchise reported revenues of 1.39 billion euros, or 13.9% higher YoY.

SNY’s genzyme portfolio

Sanofi’s genzyme portfolio includes the following speciality products:

  • oncology drugs
  • immunology drugs
  • multiple sclerosis drugs
  • rare diseases drugs

Growth in this franchise’s 3Q17 revenues was driven by strong sales of Dupizent and Kevzara from the immunology portfolio, of Aubagio and Lemtrada in the multiple sclerosis portfolio, of Aldurazyme, Cerdelga, Fabrazyme, and Myozyme from the rare diseases portfolio, and of Mozobil, Jevtana, and Zaltrap from the oncology portfolio.

SNY’s immunology portfolio

The immunology portfolio includes Dupixent and Kevraza. These drugs reported revenues of 77 million euros in 3Q17, driven by strong sales of Dupixent in US markets at 74 million euros.

SNY’s multiple sclerosis portfolio

SNY’s multiple sclerosis portfolio includes Aubagio and Lemtrada. These drugs reported revenues of 495 million euros in 3Q17, which was 15.7% higher YoY and included revenues from emerging markets.

Excluding revenues from emerging markets, the multiple sclerosis portfolio reported revenues of 481 million euros in 3Q17—a 15.5% YoY rise.

SNY’s oncology portfolio

The oncology product portfolio includes Jevtana, Mozobil, Eloxatine, Taxotere, Zaltrap, and Thymoglobulin. Oncology reported revenues of 363 million euros in 3Q17, which was 5% higher YoY and included revenues from emerging markets.

Excluding revenues from emerging markets, oncology revenues came to 262 million euros in 3Q17, which was 3.8% higher YoY, driven by strong sales of Mozobil, Zaltrap, and Jevtana.

SNY’s rare diseases portfolio

SNY’s Rare diseases portfolio includes Aldurazyme, Cerezyme, Myozyme, Febrazyme, and Cerdelga. Rare diseases reported revenues of 698 million euros, which was 2.7% higher and included revenues from emerging markets.

Excluding revenues from emerging markets, rare disease products reported revenues of 570 million euros in 3Q17, driven by strong sales of Fabrazyme, Cerdelga, and Myozyme.

Notably, the BLDRS Developed Markets 100 ADR ETF (ADRD) has 2.3% of its total investments in Sanofi ADR (SNY), 2.2% in Novo Nordisk ADR (NVO), 2.0% in GlaxoSmithKline ADR (GSK), and 2.0% in AstraZeneca ADR (AZN).

More From Market Realist